THE Pharmaceutical Benefits Scheme listing of Repatha (evolocumab) will expand to include the treatment of Australians living with a genetically inherited risk of high cholesterol.
Health Minister Greg Hunt announced the addition to the PBS from 01 Nov, with the use of Repatha expanded to cover heterozygous famlial hypercholesterolaemia (HeFH) in those with LDL-C measurements of greater than 5.0 mmol/L, or 3.0mmol/L in those with symptomatic clinical atherosclerotic cardiovascular disease.
Repatha is a PCSK9 inhibitor which targets and blocks the PCSK9 protein to assist with lowering the amount of "bad cholesterol" in the patient's blood.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Oct 18
